Jubilant Pharmova Stock Screener | Share Price & Fundamental Analysis
JUBLPHARMA
Pharmaceuticals
Share Price NSE
₹872.55
▲
5.05 (0.58%)
Share Price BSE
₹868.75
▲
2.40 (0.28%)
Track Jubilant Pharmova share price live with TickJournal's free stock screener.
Analyze Jubilant Pharmova share price history trends and compare 52-week high low
levels.
Calculate JUBLPHARMA stock fair value using fundamental analysis and view live share price charts.
Determine Jubilant Pharmova share intrinsic value and compare it with current JUBLPHARMA share price.
Record your Jubilant Pharmova trades in TickJournal's free trading journal and track your portfolio performance.
Jubilant Pharmova Market Cap
₹14,542.37 Cr.
EPS (TTM)
₹52.99
Dividend Yield
0.53%
Debt to Equity
0.55
JUBLPHARMA 52 Week High
₹1236.30
Jubilant Pharmova 52 Week Low
₹828.10
Operating Margin
17.00%
Profit Margin
7.83%
JUBLPHARMA Revenue (TTM)
₹1,928.00
EBITDA
₹341.00
Net Income
₹151.00
Total Assets
₹12,756.00
Total Equity
₹6,239.00
Jubilant Pharmova Share Price History - Stock Screener Chart
Screen JUBLPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Jubilant Pharmova Company Profile - Fundamental Screener
Screen Jubilant Pharmova company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for JUBLPHARMA shares.
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Shyam S Bhartia
ISIN
INE700A01033
Website
https://www.jubl.com
Jubilant Pharmova Balance Sheet Screener
Screen JUBLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 12,756 | 11,549 | 11,157 | 9,991 | 8,918 | 12,522 | 11,469 | 9,618 | 9,041 | 8,824 |
| Current Assets | 3,577 | 3,876 | 3,762 | 3,509 | 2,953 | 5,038 | 4,585 | 3,190 | 2,948 | 2,875 |
| Fixed Assets | 5,176 | 5,091 | 5,183 | 4,871 | 4,609 | 6,340 | 5,648 | 5,401 | 5,107 | 5,104 |
| Liabilities | ||||||||||
| Total Liabilities | 12,756 | 11,549 | 11,157 | 9,991 | 8,918 | 12,522 | 11,469 | 9,618 | 9,041 | 8,824 |
| Current Liabilities | 4,353 | 4,238 | 3,993 | 3,083 | 3,128 | 4,299 | 4,570 | 3,578 | 3,968 | 3,432 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 6,239 | 5,421 | 5,392 | 5,316 | 4,742 | 5,604 | 4,809 | 4,035 | 3,389 | 2,928 |
| Share Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves & Surplus | 6,239 | 5,418 | 5,383 | 5,303 | 4,726 | 5,588 | 4,793 | 4,071 | 3,421 | 2,951 |
Jubilant Pharmova Income Statement Screener - Profit & Revenue Analysis
Screen Jubilant Pharmova income statement and profit fundamentals.
Analyze JUBLPHARMA quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Jubilant Pharmova share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,928 | 1,891 | 1,968 | 2,137 | 1,764 | 2,130 | 1,764 | 1,823 | 1,682 | 1,575 | 1,686 | 1,714 | 1,513 | 1,452 | 1,598 |
| Expenses | 1,587 | 1,611 | 1,631 | 1,873 | 1,656 | 1,480 | 1,477 | 1,554 | 1,459 | 1,419 | 1,439 | 1,459 | 1,280 | 1,259 | 1,440 |
| EBITDA | 341 | 280 | 337 | 264 | 108 | 650 | 287 | 269 | 223 | 156 | 247 | 255 | 233 | 192 | 158 |
| Operating Profit % | 17.00% | 14.00% | 17.00% | 12.00% | 5.00% | 14.00% | 15.00% | 14.00% | 12.00% | 9.00% | 14.00% | 12.00% | 15.00% | 13.00% | 9.00% |
| Depreciation | 95 | 98 | 105 | 121 | 101 | 91 | 91 | 91 | 271 | 90 | 97 | 95 | 101 | 95 | 94 |
| Interest | 53 | 49 | 50 | 56 | 73 | 71 | 61 | 56 | 56 | 62 | 66 | 71 | 40 | 40 | 42 |
| Profit Before Tax | 206 | 154 | 190 | 93 | -54 | 500 | 144 | 131 | -86 | 25 | 98 | 101 | 106 | 69 | 36 |
| Tax | 55 | 52 | 70 | 38 | 8 | 18 | 42 | 30 | 14 | 19 | 36 | 35 | 47 | 22 | 32 |
| Net Profit | 151 | 103 | 120 | 56 | -62 | 482 | 103 | 101 | -101 | 6 | 62 | 66 | 59 | 47 | 5 |
| EPS | 9.71 | 6.49 | 7.59 | 3.52 | -3.69 | 30.44 | 6.47 | 6.37 | -6.15 | 0.40 | 3.94 | 4.22 | 3.74 | 2.96 | 0.34 |
Jubilant Pharmova Cash Flow Screener - Liquidity Fundamentals
Screen JUBLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,072 | 971 | 661 | 838 | 1,784 | 1,543 | 1,122 | 1,303 | 1,269 | 1,099 |
| Investing Activities | 513 | -596 | -474 | -323 | -727 | -267 | -1,018 | -614 | -465 | -309 |
| Financing Activities | -1,453 | -433 | -157 | -33 | -1,709 | -1,050 | 657 | -901 | -686 | -843 |
| Net Cash Flow | 132 | -58 | 30 | 482 | -652 | 225 | 761 | -212 | 117 | -52 |
Jubilant Pharmova Shareholding Pattern Screener
See Jubilant Pharmova shareholding pattern with promoter, FII, and DII holdings.
Check Jubilant Pharmova promoter holding and ownership changes for JUBLPHARMA on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 47.68% | 47.68% | 47.68% | 50.68% | 50.68% | 50.68% | 50.68% | 50.68% |
| FII Holding | 15.96% | 16.57% | 17.40% | 17.22% | 16.96% | 17.94% | 19.49% | 19.06% |
| DII Holding | 11.22% | 10.52% | 9.53% | 7.05% | 6.98% | 5.66% | 4.07% | 3.78% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 17.85% | 18.02% | 17.97% | 17.75% | 18.09% | 18.09% | 17.79% | 18.71% |
| Other Holding | 7.29% | 7.22% | 7.42% | 7.31% | 7.30% | 7.63% | 7.97% | 7.77% |
| Shareholder Count | 90,133 | 93,336 | 99,673 | 96,526 | 102,442 | 89,456 | 81,992 | 92,264 |
Jubilant Pharmova Share Dividend Screener - Share Yield Analysis
Check Jubilant Pharmova dividend history with payout and yield data.
View Jubilant Pharmova dividend details including ex-dates and amounts for JUBLPHARMA stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹5.00 | 0.55% |
| 2024-March | ₹5.00 | 0.56% |
| 2023-March | ₹5.00 | 0.88% |
| 2022-March | ₹5.00 | 1.79% |
| 2021-March | ₹5.00 | 1.29% |
| 2020-March | ₹5.00 | 0.73% |
| 2019-March | ₹4.50 | 1.81% |
| 2018-March | ₹3.00 | 0.45% |
| 2017-March | ₹3.00 | 0.36% |
Jubilant Pharmova Stock Index Membership
See which indices include Jubilant Pharmova stock.
Check JUBLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Jubilant Pharmova Market Events Screener - Corporate Actions
Get Jubilant Pharmova corporate actions including splits, bonuses, and buybacks.
Check Jubilant Pharmova stock events that may affect JUBLPHARMA share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-06 | 2026-02-06 | Quarterly Result Announcement | NA | 2.93% |
| 2025-10-31 | 2025-10-31 | Quarterly Result Announcement | NA | 1.90% |
| 2025-08-29 | 2025-08-29 | Annual General Meeting | NA | -7.13% |
| 2025-07-29 | 2025-07-29 | Quarterly Result Announcement | NA | -2.98% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 5.00 /share | 29.75% |
| 2025-05-16 | 2025-05-16 | Quarterly Result Announcement | NA | 1.03% |
| 2025-01-31 | 2025-01-31 | Quarterly Result Announcement | NA | 1.84% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -9.79% |
| 2024-08-30 | 2024-08-30 | Annual General Meeting | NA | 8.43% |
| 2024-08-02 | 2024-08-02 | Dividend | ₹ 5.00 /share | 23.06% |
| 2023-08-10 | 2023-08-10 | Dividend | ₹ 5.00 /share | 11.53% |
| 2022-08-11 | 2022-08-12 | Dividend | ₹ 5.00 /share | -11.02% |
| 2021-08-05 | 2021-08-06 | Dividend | ₹ 5.00 /share | -22.02% |
| 2021-02-01 | 2021-02-01 | Change Of Name | NA | 0.00% |
Jubilant Pharmova Competitors Screener - Peer Comparison
Screen JUBLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
Jubilant Pharmova Company Announcements - News Screener
Screen JUBLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-20 | USFDA Communication Montreal Canada | View |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-02-13 | Un-Audited Financial Results For Quarter And Nine Months Ended December 31 2025 | View |
| 2026-02-13 | Board Meeting Outcome for Meeting Held On February 06 2026 | View |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-22 | Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | View |
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-02 | Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares | View |
| 2025-12-31 | Order Received From The Income Tax Department | View |
| 2025-12-30 | Announcement under Regulation 30 (LODR)-Acquisition | View |
| 2025-12-29 | Closure of Trading Window | View |
| 2025-12-27 | Jubilant Generics Limited - Order Passed By The Assistant Commissioner Central GST Division Roorkee | View |
| 2025-12-05 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Receipt Of Adjudication Order_GST | View |
| 2025-12-02 | Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares | View |
| 2025-12-02 | Appointment Of Mr. Daniel J. OConnor As CEO Of Jubilant Therapeutics Inc. | View |
| 2025-11-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-08 | Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign" | View |
| 2025-11-04 | USFDA Communication Montreal Canada | View |